- Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol2021 | Second Faculty of Medicine
- Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group2023 | Second Faculty of Medicine
- Rearrangement of KMT2A Characterizes a Subset of Pediatric Parotid Mucoepidermoid Carcinomas Arising Metachronous to Acute Lymphoblastic Leukemia2023 | Faculty of Medicine in Pilsen
- Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia2023 | Second Faculty of Medicine
- Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study2016 | Second Faculty of Medicine
- Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: Results from an international phase III randomized study2019 | Second Faculty of Medicine
- Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype2021 | First Faculty of Medicine
- Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol2022 | Second Faculty of Medicine